Online citations, reference lists, and bibliographies.
← Back to Search

Nanocarriers In Ocular Drug Delivery: An Update Review.

Sheetu Wadhwa, R. Paliwal, S. Paliwal, S. Vyas
Published 2009 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Controlled drug delivery to eye is one of the most challenging fields of pharmaceutical research. Low drug-contact time and poor ocular bioavailability due to drainage of solution, tear turnover and its dilution or lacrimation are the problems associated with conventional systems. In addition, anatomical barriers and physiological conditions of eye are also important parameters which control designing of drug delivery systems. Nanosized carriers like micro/nano-suspensions, liposome, niosome, dendrimer, nanoparticles, ocular inserts, implants, hydrogels and prodrug approaches have been developed for this purpose. These novel systems offer manifold advantages over conventional systems as they increase the efficiency of drug delivery by improving the release profile and also reduce drug toxicity. Conventional delivery systems get diluted with tear, washed away through the lacrimal gland and usually require administering at regular time intervals whereas nanocarriers release drug at constant rate for a prolonged period of time and thus enhance its absorption and site specific delivery. This review presents an overview of the various aspects of the ocular drug delivery, with special emphasis on nanocarrier based strategies, including structure of eye, its barriers, delivery routes and the challenges/limitations associated with development of novel nanocarriers. The recent progresses in therapy of ocular disease like gene therapy have also been included so that future options should also be considered from the delivery point of view. Recent progress in the delivery of proteins and peptides via ocular route has also been incorporated for reader benefit.
This paper references
10.1016/J.BIOMATERIALS.2006.11.028
Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP).
Y. Diebold (2007)
10.1167/iovs.08-2077
Effective treatment of ocular HSK with a human apolipoprotein E mimetic peptide in a mouse eye model.
P. S. Bhattacharjee (2008)
10.1016/j.ajo.2008.08.026
Femtosecond lasers in ophthalmology.
H. Soong (2009)
10.1007/s11095-008-9694-0
Recent Perspectives in Ocular Drug Delivery
Ripal Gaudana (2008)
10.1080/107175400455128
Pluronic F127-based ocular delivery system containing biodegradable polyisobutylcyanoacrylate nanocapsules of pilocarpine.
S. D. Desai (2000)
10.1016/J.EXER.2007.08.006
A novel bubble liposome and ultrasound-mediated gene transfer to ocular surface: RC-1 cells in vitro and conjunctiva in vivo.
T. Yamashita (2007)
10.1097/IAE.0b013e31802ea591
OCULAR TISSUE DISTRIBUTION OF BETAMETHASONE AFTER ANTERIOR-EPISCLERAL, POSTERIOR-EPISCLERAL, AND ANTERIOR-INTRASCLERAL PLACEMENT OF NONBIODEGRADABLE IMPLANTS
Komei Okabe (2007)
10.1167/IOVS.04-1076
Preclinical evaluation of a novel episcleral cyclosporine implant for ocular graft-versus-host disease.
H. Kim (2005)
10.1097/IJG.0b013e3180391a18
Optic Nerve Restoration: New Perspectives
N. Bull (2007)
10.1016/J.EXER.2004.06.023
Inhibition of in vitro VEGF expression and choroidal neovascularization by synthetic dendrimer peptide mediated delivery of a sense oligonucleotide.
R. J. Marano (2004)
10.1186/1740-2557-2-6
Expression of TNF inhibitor gene in the lacrimal gland promotes recovery of tear production and tear stability and reduced immunopathology in rabbits with induced autoimmune dacryoadenitis
M. Trousdale (2005)
10.1016/S0378-5173(02)00234-X
In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate.
A. El-Kamel (2002)
10.2217/17435889.2.1.11
Ocular drug delivery: nanomedicine applications.
J. Vandervoort (2007)
10.1208/aapsj0903044
Preparation and ocular pharmacokinetics of ganciclovir liposomes
Y. Shen (2008)
10.1124/DMD.30.6.670
Ocular disposition of ganciclovir and its monoester prodrugs following intravitreal administration using microdialysis.
S. Macha (2002)
10.1016/S0378-5173(01)00825-0
In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride.
S. Miyazaki (2001)
Luteinizing hormone-releasing hormone agonist and transferrin functionalizations enhance nanoparticle delivery in a novel bovine ex vivo eye model.
U. Kompella (2006)
10.1089/jop.2007.0088
Corneal permeation studies of everolimus microemulsion.
Yücel Başpınar (2008)
[Effect of adenovirally delivered brain-derived neurotrophic factor on superoxide dismutase within the retina of experimentally injured optic nerve of rat eyes].
Dan Hu (2002)
10.1208/pt070127
Preparation and characterization of Eudragit Retard nanosuspensions for the ocular delivery of cloricromene
R. Pignatello (2008)
10.1016/J.IJPHARM.2007.01.019
Study of the extent of ocular absorption of acetazolamide from a developed niosomal formulation, by microdialysis sampling of aqueous humor.
Deepika Aggarwal (2007)
10.1016/J.ADDR.2006.07.027
Challenges and obstacles of ocular pharmacokinetics and drug delivery.
A. Urtti (2006)
10.1211/jpp.59.5.0002
Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye drops
T. Loftsson (2007)
10.1371/journal.pone.0000038
Efficient Non-Viral Ocular Gene Transfer with Compacted DNA Nanoparticles
R. Farjo (2006)
10.1016/S0079-6123(08)01135-7
Stem cells for neuroprotection in glaucoma.
N. Bull (2008)
10.1167/IOVS.05-0889
Gene transfer to corneal epithelium and keratocytes mediated by ultrasound with microbubbles.
S. Sonoda (2006)
10.1034/J.1600-0420.2002.800205.X
Cyclodextrins in eye drop formulations: enhanced topical delivery of corticosteroids to the eye.
T. Loftsson (2002)
10.1007/s12272-001-1266-6
Chitosan based nanocarriers for indomethacin ocular delivery
A. Badawi (2008)
10.1002/JPS.10227
Ocular tolerability of Eudragit RS100 and RL100 nanosuspensions as carriers for ophthalmic controlled drug delivery.
R. Pignatello (2002)
10.1016/J.IJPHARM.2006.05.053
Biodegradable scleral implants as new triamcinolone acetonide delivery systems.
O. Felt-Baeyens (2006)
10.1007/s10585-007-9085-7
Inhibition of a vascular ocular tumor growth by IL-12 gene transfer
A. Albini (2007)
Microemulsions as potential ocular drug delivery systems: phase diagrams and physical properties depending on ingredients.
A. Radomska-Soukharev (2005)
10.1002/JPS.21201
Liposomal phospholipid preparations of chloramphenicol for ophthalmic applications.
S. Mahmoud (2008)
10.1023/B:PHAM.0000026432.75781.cb
Chitosan Nanoparticles as New Ocular Drug Delivery Systems: in Vitro Stability, in Vivo Fate, and Cellular Toxicity
A. M. de Campos (2004)
10.2174/1389450053765914
Colloidal carriers for ophthalmic drug delivery.
R. Mainardes (2005)
10.1016/S1726-4901(08)70005-4
Comparison of Multiple Reduced‐dose and Standard Light Application in Photodynamic Therapy in an Animal Model of Choroidal Neovascularization
S. Sheu (2008)
10.1089/HUM.2006.17.167
Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial.
P. Campochiaro (2006)
10.1016/j.ajo.2008.02.008
Photodynamic therapy for predominantly hemorrhagic lesions in neovascular age-related macular degeneration.
S. Ahmad (2008)
10.1016/J.JCONREL.2007.05.004
Wanted and unwanted properties of surface PEGylated nucleic acid nanoparticles in ocular gene transfer.
N. Sanders (2007)
10.1111/j.1442-9071.2004.00914.x
New vehicle based on a microemulsion for topical ocular administration of dexamethasone
S. L. Fialho (2004)
10.1016/J.EXER.2006.03.023
Improved transduction of human corneal epithelial progenitor cells with cell-targeting adenoviral vectors.
Z. Chen (2006)
10.1038/sj.gt.3301485
In vivo gene delivery into ocular tissues by eye drops of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) polymeric micelles
J. Liaw (2001)
10.1080/10611860290022660
Efficacy of Ganciclovir-loaded Nanoparticles in Human Cytomegalovirus (HCMV)-infected Cells
M. Merodio (2002)
10.1016/J.OHC.2006.05.007
Interference RNA technology in the treatment of CNV.
M. Tolentino (2006)
10.1016/J.EJPS.2005.05.003
A water-soluble prodrug of cyclosporine A for ocular application: a stability study.
F. Lallemand (2005)
10.1016/S1350-9462(01)00017-9
Microemulsions as ocular drug delivery systems: recent developments and future challenges
T. Vandamme (2002)
10.1016/j.nano.2008.07.003
Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application.
Sagar M. Agnihotri (2009)
10.1016/j.exer.2008.04.002
Hyaluronic acid coated poly-epsilon-caprolactone nanospheres deliver high concentrations of cyclosporine A into the cornea.
I. Yenice (2008)
10.1007/s10856-008-3486-2
Alginate microsphere-collagen composite hydrogel for ocular drug delivery and implantation
Wenguang Liu (2008)
10.1089/JOP.2007.0002
Inhibitory efficacy of intravitreal dexamethasone acetate-loaded PLGA nanoparticles on choroidal neovascularization in a laser-induced rat model.
Jianfeng Xu (2007)
10.1136/bjo.77.11.713
A comparison of the efficacy and duration of action of topically applied proxymetacaine using a novel ophthalmic delivery system versus eye drops in healthy young volunteers.
J. Lawrenson (1993)
10.1089/JOP.2000.16.419
Enhancement of the mydriatic response to tropicamide by bioadhesive polymers.
R. Herrero-Vanrell (2000)
10.1023/A:1018959231951
Targeted Gene Delivery to Alveolar Macrophages via Fc Receptor-Mediated Endocytosis
Y. Rojanasakul (2004)
10.1167/IOVS.05-0495
Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance.
Amalia Enríquez de Salamanca (2006)
10.3109/02652049109021873
Studies on the transport pathway of PBCA nanoparticles in ocular tissues.
A. Zimmer (1991)
10.1016/J.EJPB.2007.09.009
Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterisation.
S. Motwani (2008)
10.2165/00003088-199018040-00001
Ocular Drug Delivery
R. Schoenwald (1990)
10.1016/J.IJPHARM.2006.12.038
Development of a poloxamer analogs/carbopol-based in situ gelling and mucoadhesive ophthalmic delivery system for puerarin.
Hongyi Qi (2007)
10.1016/J.IJPHARM.2006.01.029
Study of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin.
Zhidong Liu (2006)
10.1167/IOVS.04-0091
Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging.
H. Kim (2004)
Discoidal niosome based controlled ocular delivery of timolol maleate.
S. Vyas (1998)
10.1023/A:1023290514575
Influence of Preparation Conditions on Acyclovir-Loaded Poly-d,l-Lactic Acid Nanospheres and Effect of PEG Coating on Ocular Drug Bioavailability
C. Giannavola (2004)
10.1159/000140228
Application of Microemulsions in Dermal and Transdermal Drug Delivery
P. Santos (2008)
10.1016/S0079-6123(08)01116-3
Laser therapies for glaucoma: new frontiers.
G. Scuderi (2008)
10.1016/J.ADDR.2005.09.004
Topical and systemic drug delivery to the posterior segments.
Patrick M Hughes (2005)
10.1016/J.IJPHARM.2007.02.024
Non-phospholipid vesicles as carriers for peptides and proteins: production, characterization and stability studies.
R. Cortesi (2007)
Photodynamic therapy of ocular melanoma with bis silicon 2,3-naphthalocyanine in a rabbit model.
R. Hill (1995)
10.1096/fj.05-4737fje
Plasmid electrotransfer of eye ciliary muscle: principles and therapeutic efficacy using hTNF‐α soluble receptor in uveitis
C. Bloquel (2006)
10.1211/jpp.57.12.0005
Size‐dependent disposition of nanoparticles and microparticles following subconjunctival administration
A. Amrite (2005)
10.1089/108076802321021054
Biodegradable calcium phosphate nanoparticles as a new vehicle for delivery of a potential ocular hypotensive agent.
T. Chu (2002)
10.3109/02652048609031575
Ocular drug delivery of progesterone using nanoparticles.
V. Li (1986)
10.1016/0378-5173(92)90340-8
Pilocarpine bioavailability from a mucoadhesive liposomal ophthalmic drug delivery system
A. M. Durrani (1992)
[Preparation and in vitro corneal retention behavior of novel cationic microemulsion/in situ gel system].
Shou-wei Ma (2008)
10.1016/0169-409X(95)00017-2
Microspheres and nanoparticles used in ocular delivery systems
A. Zimmer (1995)
10.1158/0008-5472.CAN-07-2352
Treatment of invasive retinoblastoma in a murine model using an oncolytic picornavirus.
L. Wadhwa (2007)
10.1002/1520-6017(200103)90:3<288::AID-JPS4>3.0.CO;2-5
Ocular tolerability and in vivo bioavailability of poly(ethylene glycol) (PEG)-coated polyethyl-2-cyanoacrylate nanosphere-encapsulated acyclovir.
M. Fresta (2001)
10.1016/J.JCONREL.2007.09.006
Zero-order therapeutic release from imprinted hydrogel contact lenses within in vitro physiological ocular tear flow.
M. Ali (2007)
A new vitreal drug delivery system using an implantable biodegradable polymeric device.
H. Kimura (1994)
10.1023/A:1018977130559
Design of New Formulations for Topical Ocular Administration: Polymeric Nanocapsules Containing Metipranolol
C. Losa (2004)
10.1002/JPS.20685
Flurbiprofen loaded biodegradable nanoparticles for ophtalmic administration.
E. Vega (2006)
Ocular and systemic bio-distribution of rhodamine-conjugated liposomes loaded with VIP injected into the vitreous of Lewis rats
S. Camelo (2007)
10.1016/S0142-9612(02)00080-7
Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application.
R. Pignatello (2002)
10.1517/17425247.5.5.567
Ocular novel drug delivery: impacts of membranes and barriers
J. Barar (2008)
10.1089/JOP.2006.22.231
Vitreal pharmacokinetics of dipeptide monoester prodrugs of ganciclovir.
S. Majumdar (2006)
10.1016/j.jconrel.2007.11.016
Charged nanoparticles delivery to the eye using hydrogel iontophoresis.
E. Eljarrat-Binstock (2008)
10.1089/HUM.2005.16.1037
Tetracycline-inducible viral interleukin-10 intraocular gene transfer, using adeno-associated virus in experimental autoimmune uveoretinitis.
J. R. Smith (2005)
10.1016/J.JCONREL.2005.05.020
Transcorneal and transscleral iontophoresis of dexamethasone phosphate using drug loaded hydrogel.
E. Eljarrat-Binstock (2005)
10.2174/138920007779815977
Ocular disposition, pharmacokinetics, efficacy and safety of nanoparticle-formulated ophthalmic drugs.
Hai-zhi Bu (2007)
10.1023/A:1006137100444
Retinal toxicity of liposome-incorporated and free ofloxacin after intravitreal injection in rabbit eyes
B. Wiechens (2004)
10.1016/j.jcrs.2007.09.040
Outcomes of phacoemulsification in fellow eyes of patients with unilateral pseudoexfoliation: Single‐surgeon series
B. Shingleton (2008)
DESIGN AND CHARACTERIZATION OF BIOADHESIVE IN-SITU GELLING OCULAR INSERTS OF GATIFLOXACIN SESQUIHYDRATE
D. Mishra (2008)
10.1002/eji.200425022
Intraocular injection of tamoxifen‐loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis
Y. de Kozak (2004)
10.1016/S0014-4835(63)80001-9
The inbibition pressure of the corneal stroma.
B. Hedbys (1963)
10.1016/j.visres.2007.07.012
Nanoparticle applications in ocular gene therapy
Xue Cai (2008)
10.1016/S0378-5173(99)00265-3
Preparation and evaluation of liposomal formulations of tropicamide for ocular delivery.
M. Nagarsenker (1999)
10.1038/sj.gt.3300886
Activated polyamidoamine dendrimers, a non-viral vector for gene transfer to the corneal endothelium
T. Hudde (1999)
10.1016/J.IJPHARM.2004.10.026
Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system.
Deepika Aggarwal (2005)
10.1208/pt040345
Effect of hydroxypropyl beta cyclodextrin complexation on aqueous solubility, stability, and corneal permeation of acyl ester prodrugs of ganciclovir
G. Tirucherai (2008)
Methazolamide 1% in cyclodextrin solution lowers IOP in human ocular hypertension.
E. Gudmundsdóttir (2000)
10.1097/IJG.0b013e318031676c
The Effect of Selective Laser Trabeculoplasty on Intraocular Pressure in Patients With Intravitreal Steroid-induced Elevated Intraocular Pressure
B. Rubin (2008)
10.1211/0022357023691
Nanosuspensions: a promising drug delivery strategy
V. Patravale (2004)
10.1016/J.JCONREL.2007.07.009
In situ-forming hydrogels for sustained ophthalmic drug delivery.
Basavaraj K Nanjawade (2007)
10.1089/JOP.2006.22.465
Corneal absorption and anterior chamber pharmacokinetics of dipeptide monoester prodrugs of ganciclovir (GCV): in vivo comparative evaluation of these prodrugs with Val-GCV and GCV in rabbits.
Sriram Gunda (2006)
10.1016/J.IJPHARM.2005.08.024
Synthesis, physicochemical properties and antiviral activities of ester prodrugs of ganciclovir.
Kunal Patel (2005)
10.1016/j.ijpharm.2008.04.023
Solid lipid nanoparticles for retinal gene therapy: transfection and intracellular trafficking in RPE cells.
A. Del Pozo-Rodríguez (2008)
10.1016/J.IJPHARM.2003.09.016
Vesicular systems in ocular drug delivery: an overview.
I. P. Kaur (2004)
10.1016/0378-5173(96)04438-9
Amphiphilic properties of pilocarpine prodrugs
P. Saarinen-Savolainen (1996)
10.4103/0301-4738.27947
Retinal toxicity of intravitreally injected plain and liposome formulation of fluconazole in rabbit eye.
T. Velpandian (2006)
10.1016/J.BIOMATERIALS.2004.07.055
Controlled release of plasmid DNA from photo-cross-linked pluronic hydrogels.
Ki Woo Chun (2005)
[Preparation of diclofenac sodium liposomes and its ocular pharmacokinetics].
Kao-xiang Sun (2006)
Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration
A. Amrite (2008)
10.1002/JPS.2600630810
Ocular evaluation of methylcellulose vehicle in albino rabbits.
S. Chrai (1974)
10.1088/1748-6041/2/4/006
Controlled release gelatin hydrogels and lyophilisates with potential application as ocular inserts.
M. Natu (2007)
10.1023/B:PHAM.0000019300.04836.51
Evaluation of Generation 2 and 3 Poly(Propylenimine) Dendrimers for the Potential Cellular Delivery of Antisense Oligonucleotides Targeting the Epidermal Growth Factor Receptor
A. Hollins (2004)
10.1016/j.drudis.2007.10.021
Nanotechnology in ocular drug delivery.
S. Sahoo (2008)
10.1016/J.IJPHARM.2007.03.011
Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs.
M. Kassem (2007)
10.3129/CAN.J.OPHTHALMOL.I07-049
Ocular drug delivery: molecules, cells, and genes.
X. Liu (2007)
10.1124/MOL.105.015628
Vascular Targeting of Ocular Neovascularization with a Vascular Endothelial Growth Factor121/Gelonin Chimeric Protein
Hideo Akiyama (2005)
10.1016/J.JCONREL.2004.09.015
Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide.
Th F Vandamme (2005)
[Polymeric nanoparticles: new systems for improving ocular bioavailability of drugs].
M. J. Alonso (2001)
10.1016/j.ijpharm.2008.05.024
Synthesis, metabolism and cellular permeability of enzymatically stable dipeptide prodrugs of acyclovir.
Ravi S. Talluri (2008)
10.1016/S0378-5173(97)00362-1
Properties of acyclovir-containing liposomes for potential ocular delivery
S. Law (1998)
10.1208/aapsj060325
Neural retina limits the nonviral gene transfer to retinal pigment epithelium in an in vitro bovine eye model
L. Pitkänen (2008)
10.1097/ICL.0b013e3181812ba2
Uptake and Release of Ciprofloxacin-HCl From Conventional and Silicone Hydrogel Contact Lens Materials
Alex Hui (2008)
10.1016/S0378-5173(97)00083-5
Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers
P. Calvo (1997)
10.1080/10837450801949566
Alginate Inserts Loaded with Epidermal Growth Factor for the Treatment of Keratoconjunctivitis Sicca
C. Koelwel (2008)
10.1038/gt.2008.16
Bioadhesive hyaluronan–chitosan nanoparticles can transport genes across the ocular mucosa and transfect ocular tissue
M. Fuente (2008)
10.1016/j.nano.2008.06.003
Ocular nanoparticle toxicity and transfection of the retina and retinal pigment epithelium.
Tarl W. Prow (2008)
10.1016/S0161-6420(78)35668-2
Dipivalyl epinephrine: a new pro-drug in the treatment of glaucoma.
A. I. Mandell (1978)
10.1016/J.JCONREL.2004.10.004
Cyclodextrin formulation of dorzolamide and its distribution in the eye after topical administration.
H. Sigurdsson (2005)
10.1016/J.EJPB.2005.09.006
Studies on the stability of the chloramphenicol in the microemulsion free of alcohols.
Feng-Feng Lv (2006)
10.1038/sj.gt.3302579
Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity
R. J. Marano (2005)
10.1080/10611860701453653
Muco-adhesive multivesicular liposomes as an effective carrier for transmucosal insulin delivery
A. Jain (2007)
10.1167/IOVS.02-1068
Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles.
Jean-Louis Bourges (2003)
10.1111/J.1755-3768.1974.TB01101.X
Permeability of horseradish peroxidase in the rabbit corneal epithelium.
A. Tønjum (1974)
10.1016/j.jsbmb.2007.10.002
The in vitro immunomodulatory activity of a synthetic brassinosteroid analogue would account for the improvement of herpetic stromal keratitis in mice
F. M. Michelini (2008)
10.1208/s12249-008-9105-1
Niosome-Encapsulated Gentamicin for Ophthalmic Controlled Delivery
G. Abdelbary (2008)
10.1002/jgm.231
High‐level gene transfer to the cornea using electroporation
K. Blair-Parks (2002)
10.2174/156720106777731118
Applications of microemulsion based drug delivery system.
K. Jadhav (2006)
10.1021/MP0498998
In vivo ocular pharmacokinetics of acyclovir dipeptide ester prodrugs by microdialysis in rabbits.
Banmeet S. Anand (2006)
10.1016/J.EJPHAR.2005.02.019
Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model.
S. Ayalasomayajula (2005)
10.1517/17425247.3.4.511
Chemical modification and formulation approaches to elevated drug transport across cell membranes
S. Majumdar (2006)
10.2174/157341308783591816
Solid Lipid Nanoparticles (SLNs) as a Rising Tool in Drug Delivery Science: One Step Up in Nanotechnology
S. Vyas (2008)
Effect of betamethasone phosphate–loaded polyactide nanoparticles on experimental autoimmune uveoretinitis
Tsutomu Sakai (2004)
10.1016/S1350-9462(97)00002-5
Ophthalmic drug delivery systems—Recent advances
C. L. Bourlais (1998)
10.1016/S0378-5173(02)00080-7
Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin.
R. Cavalli (2002)
Improved corneal penetration of timolol by prodrugs as a means to reduce systemic drug load.
S. Chang (1987)
10.1136/bjo.2006.103168
Intravitreal injection of Tacrolimus (FK506) suppresses ongoing experimental autoimmune uveoretinitis in Rats
K. Oh-i (2007)
10.1016/S0378-5173(02)00421-0
Effect of chitosan on in vitro release and ocular delivery of ofloxacin from erodible inserts based on poly(ethylene oxide).
G. Di Colo (2002)
10.1002/JPS.1162
Ocular absorption behavior of palmitoyl tilisolol, an amphiphilic prodrug of tilisolol, for ocular drug delivery.
S. Kawakami (2001)
10.1016/0378-5173(96)04627-3
Studies showing the effect of enzymes on the stability of ester prodrugs of propranolol and oxprenolol in biological samples
C. Geraldine (1996)
10.1089/JOP.2005.21.420
Inhibition of experimental autoimmune anterior uveitis by adenovirus-mediated transfer of the interleukin-10 gene.
I. Fang (2005)
10.1016/j.ophtha.2008.08.026
Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage.
S. Chen (2008)
10.1016/j.drudis.2007.12.005
Ophthalmic light sensitive nanocarrier systems.
Jennifer G Christie (2008)
10.2174/187221108783331410
Recent patents on ocular drug delivery systems.
B. Conway (2008)
10.1016/J.IJPHARM.2007.04.013
Gels and liposomes in optimized ocular drug delivery: studies on ciprofloxacin formulations.
L. Budai (2007)
10.1016/J.JCONREL.2007.05.009
Poly(N-isopropylacrylamide)-chitosan as thermosensitive in situ gel-forming system for ocular drug delivery.
Y. Cao (2007)
Drug delivery for posterior segment eye disease.
D. Geroski (2000)
10.1167/iovs.07-1077
Novel hyaluronic acid-chitosan nanoparticles for ocular gene therapy.
M. de la Fuente (2008)
10.1136/bjo.2007.131771
Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema
Z K Ockrim (2008)
10.1167/IOVS.03-1294
Nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase: a role in high glucose-induced apoptosis in retinal Müller cells.
L. Kusner (2004)
10.1016/S0378-5173(99)00059-9
The in vitro evaluation of polyethylene glycol esters of hydrocortisone 21-succinate as ocular prodrugs.
S. M. Foroutan (1999)
10.1002/JPS.2600770103
Mechanisms of corneal drug penetration. I: In vivo and in vitro kinetics.
G. Grass (1988)
10.1016/J.IJPHARM.2007.09.005
Pluronic F127-g-poly(acrylic acid) copolymers as in situ gelling vehicle for ophthalmic drug delivery system.
Wen-di Ma (2008)
10.1089/jop.2008.0031
Development of effective ocular preparations of antifungal agents.
I. P. Kaur (2008)
10.1097/IAE.0b013e31817d8bf2
OUTCOME OF FLUOCINOLONE ACETONIDE IMPLANT (RETISERT™) REIMPLANTATION FOR CHRONIC NONINFECTIOUS POSTERIOR UVEITIS
M. Taban (2008)
10.1016/j.ijpharm.2008.05.028
Ophthalmic delivery of Cyclosporine A from Brij-97 microemulsion and surfactant-laden p-HEMA hydrogels.
Yash Kapoor (2008)
10.1038/SJ.MT.6300324
Cell-penetrating peptide for enhanced delivery of nucleic acids and drugs to ocular tissues including retina and cornea.
L. A. Johnson (2008)
10.2353/AJPATH.2007.060487
Proangiogenic role of ephrinB1/EphB1 in basic fibroblast growth factor-induced corneal angiogenesis.
T. Kojima (2007)
10.1167/IOVS.06-1305
Downregulation of endotoxin-induced uveitis by intravitreal injection of vasoactive intestinal Peptide encapsulated in liposomes.
Laure Lajavardi (2007)
10.1016/J.EJPB.2005.01.009
Cell culture models of the ocular barriers.
M. Hornof (2005)
10.1016/J.IJPHARM.2005.09.023
Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide.
Ahmed S. Guinedi (2005)
10.1038/gt.2008.115
Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization
P. Pecháň (2009)
10.1080/02652040400008515
Polycarboxylic acid nanoparticles for ophthalmic drug delivery: an ex vivo evaluation with human cornea
T. K. De (2004)
10.1016/0378-5173(95)04376-4
Intraocular drug delivery. In vitro release studies of 5-fluorouracil from N1-alkoxycarbonyl prodrugs in silicone oil
B. Steffansen (1996)
10.1016/J.IJPHARM.2004.03.013
In vivo gene transfection via intravitreal injection of cationic liposome/plasmid DNA complexes in rabbits.
S. Kawakami (2004)
10.1001/ARCHOPHT.122.4.621
Stem cell therapy for ocular disorders.
L. Levin (2004)
10.2174/1567201043480054
Development of topically effective formulations of acetazolamide using HP-beta-CD-polymer co-complexes.
I. P. Kaur (2004)
10.1208/pt0801001
Liposomes as an ocular delivery system for acetazolamide: In vitro and in vivo studies
Rania M. Hathout (2008)
10.1016/J.JCONREL.2004.05.016
Starch acetate microparticles for drug delivery into retinal pigment epithelium-in vitro study.
L. Tuovinen (2004)
10.1016/J.EJPB.2003.10.018
PLGA microspheres for the ocular delivery of a peptide drug, vancomycin using emulsification/spray-drying as the preparation method: in vitro/in vivo studies.
E. Gavini (2004)
10.1016/0731-7085(89)80030-5
Microemulsions as topical delivery vehicles: ocular administration of timolol.
M. Gasco (1989)
Transscleral delivery of bioactive protein to the choroid and retina.
J. Ambati (2000)
RNA interference targeting transforming growth factor-β type II receptor suppresses ocular inflammation and fibrosis
H. Nakamura (2004)
10.1016/J.CARBPOL.2007.11.007
Chitosan nanoparticles loaded with dorzolamide and pramipexole
Sofia A. Papadimitriou (2008)
10.1016/S0928-0987(02)00057-X
Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen.
R. Pignatello (2002)
10.1016/S0378-5173(00)00508-1
Ketorolac entrapped in polymeric micelles: preparation, characterisation and ocular anti-inflammatory studies.
A. Gupta (2000)
10.1016/j.drudis.2007.11.002
Current and future ophthalmic drug delivery systems. A shift to the posterior segment.
Eva M. del Amo (2008)
10.1016/j.ijpharm.2008.03.015
Ocular pharmacokinetics of acyclovir amino acid ester prodrugs in the anterior chamber: evaluation of their utility in treating ocular HSV infections.
Suresh Katragadda (2008)



This paper is referenced by
10.1007/978-1-4419-9920-7_9
Advances in Biodegradable Ocular Drug Delivery Systems
S. Lee (2011)
10.1201/B15642-4
Nanotechnology Applications in Ophthalmology
Eman Elhawy (2013)
10.1002/mabi.201100419
Nanomaterials for ocular drug delivery.
Shengyan Liu (2012)
10.1016/j.xphs.2020.01.022
Novel polyvinyl pyrrolidone loaded olopatadine HCl laden doughnut contact lens to treat allergic conjunctivitis.
Yushun Xue (2020)
10.1208/s12249-017-0710-8
PLGA Nanoparticles as Subconjunctival Injection for Management of Glaucoma
H. A. Salama (2017)
10.1002/APP.47863
Effect of nanoscale confinement on molecular mobility and drug release properties of cellulose acetate/sulindac nanofibers
J. Chung (2019)
ON APPLICATIONS OF DENDRIMERS IN TRANSDERMAL DRUG DELIVERY
Verma Priyanka (2012)
10.1155/2011/863734
Recent Applications of Liposomes in Ophthalmic Drug Delivery
G. P. Mishra (2011)
10.1016/B978-0-12-384935-9.10005-7
Ocular Delivery of Peptides and Proteins
S. P. Vyas (2011)
ISSN: 2249-0337 Review Article Current Trends Towards an Ocular Drug Delivery System: Review
Sandeep C. Atram (2013)
10.1016/j.addr.2013.01.001
Expand classical drug administration ways by emerging routes using dendrimer drug delivery systems: a concise overview.
S. Mignani (2013)
10.1007/978-3-030-41858-8_12
Effect of Drugs and Nanoformulation on Ocular Cells in Various Disease States
Sanjeev Kumar Paikra (2020)
10.1007/978-3-319-70299-5_12
Nanotechnological Interventions for Drug Delivery in Eye Diseases
A. Ingle (2017)
10.1007/s11051-012-1374-7
Human serum albumin as protecting agent of silver nanoparticles: role of the protein conformation and amine groups in the nanoparticle stabilization
E. Alarcon (2013)
10.1007/978-1-62703-761-7_25
Method for retinal gene repair in neonatal mouse.
M. Dernigoghossian (2014)
12 Drops , Drops , and More Drops
J. Walt ()
10.1002/9781119962977.CH14
Chitosan‐Based Systems for Ocular Delivery of Biopharmaceuticals
Suresh P. Vyas (2012)
10.1124/jpet.119.256933
Ocular Drug Delivery: Present Innovations and Future Challenges
Vrinda Gote (2019)
10.1007/s40005-018-0404-6
Pharmaceutical challenges and perspectives in developing ophthalmic drug formulations
Pooja Maharjan (2018)
10.1201/B16966-9
CURRENT ADVANCES IN NANOMEDICINE: APPLICATIONS IN CLINICAL MEDICINE AND SURGERY
I Joseph Kalyan Raj (2014)
10.2174/2210303109666190404143906
Chitosan Applications on Pharmaceutical Sciences: A Review
Cintia Alejandra Briones Nieva (2019)
10.2174/1872211314666191224115211
Nano-Based Drug Delivery System: Recent Strategies for the Treatment of Ocular Disease and Future Perspective
Zufika Qamar (2019)
Dosage forms in therapy of posterior segments of the eye
Lucie Pospěchová (2016)
10.2741/E565
Gene therapy in age related macular degeneration and hereditary macular disorders.
K. Kinnunen (2012)
10.2147/DDDT.S153405
A novel ocular delivery of brinzolamide based on gellan gum: in vitro and in vivo evaluation
J. Sun (2018)
10.3109/10717544.2014.923065
Colloidal drug delivery system: amplify the ocular delivery
Ameeduzzafar (2016)
10.5772/INTECHOPEN.76797
Photonic Crystal Waveguides
D. Usanov (2018)
10.2174/138955709791012292
Chitosan and its role in ocular therapeutics.
Sheetu Wadhwa (2009)
10.1016/j.jconrel.2013.09.016
Self-assembled phenylalanine-α,β-dehydrophenylalanine nanotubes for sustained intravitreal delivery of a multi-targeted tyrosine kinase inhibitor.
J. J. Panda (2013)
Cationic Lipid Nanomedicines for the treatment of Diabetic retinopathy
J. Fangueiro (2015)
10.1016/j.xphs.2020.02.008
In vitro and in vivo studies of polyvinyl pyrrolidone coated sparfloxacin loaded ring contact lens to treat conjunctivitis.
Wenying Ran (2020)
10.4236/jct.2011.23045
Nanoparticles in Drug Delivery and Cancer Therapy: The Giant Rats Tail
V. V. Prabhu (2011)
See more
Semantic Scholar Logo Some data provided by SemanticScholar